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Background—Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and 
other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients.
Methods and Results—We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-
converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction 
in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison 
with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure 
(520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74–0.94; P=0.003) or an emergency department visit for 
worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52–0.85; P=0.001). The patients in the LCZ696 
group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to 
require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents 
(31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk 
reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after 
randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. 
LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro–B-
type natriuretic peptide and troponin) versus enalapril.
Conclusions—Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure 
more effectively than angiotensin-converting enzyme inhibition.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255. (Circulation. 2015;131:54–61. 
DOI: 10.1161/CIRCULATIONAHA.114.013748.)
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Although heart failure increases the risk of death, nonfatal worsening of symptoms is the most common problem 
encountered by patients, who experience progressive impair-
ment of functional capacity and quality of life.1 Nonfatal 
worsening may require intensification of oral medications or 
it can necessitate emergent treatment, including hospitaliza-
tion, intensive care, or expensive medical or surgical interven-
tions.1,2 Therefore, in addition to prolonging survival, a major 
goal in the management of chronic heart failure is mainte-
nance of the clinical stability of patients, specifically by pre-
venting nonfatal worsening of heart failure with its attendant 
consequences.
Editorial see p 11 
Clinical Perspective on p 61
The activation of detrimental neurohormonal pathways con-
tributes to the clinical progression of heart failure.3 However, 
despite the use of angiotensin-converting enzyme (ACE) 
inhibitors, β-blockers, and mineralocorticoid receptor antago-
nists patients remain at high risk of worsening heart failure.4 
Such progression may be related to inadequate activation of or 
a diminished response to the compensatory actions of endog-
enous adaptive neurohormonal systems.5–7 Several peptides 
(ie, natriuretic peptides, bradykinin, and adrenomedullin) can 
attenuate vasoconstriction and sodium retention, and retard 
cardiac and vascular hypertrophy and remodeling, and thus act 
to ameliorate many of the pathophysiological abnormalities 
of heart failure.8–10 Neprilysin is the key enzyme responsible 
for the breakdown of these peptides, and its activity may be 
increased in heart failure.11 Inhibition of neprilysin enhances 
the effects of these beneficial vasoactive substances and exerts 
favorable effects in patients with heart failure, when combined 
with existing agents that act on detrimental neurohormonal 
systems.12 Concurrent inhibition of angiotensin synthesis or 
action is particularly important, because neprilysin inhibition 
alone is accompanied by the activation of the renin-angiotensin 
system, possibly because angiotensin itself may be a substrate 
for neprilysin.13,14 Although the actions of angiotensin may be 
attenuated by inhibition of the ACE, simultaneous blockade 
of ACE and neprilysin can lead to serious angioedema.15,16 
Therefore, the preferred approach to parallel modulation of 
these neurohormonal systems is the combined use of a nepri-
lysin inhibitor with an angiotensin receptor blocker.17
The PARADIGM-HF (Prospective comparison of ARNI 
with ACEI to Determine Impact on Global Mortality and mor-
bidity in Heart Failure) trial compared the long-term effects of 
LCZ696—a complex of the neprilysin inhibitor sacubitril and 
the angiotensin receptor blocker valsartan—with enalapril in 
patients with heart failure with mild-to-moderate symptoms.18 
The trial demonstrated the superiority of LCZ696 over enala-
pril on both death from any cause, and on death from cardio-
vascular causes.12 Here, we describe the incremental effects 
of LCZ696 over enalapril on the nonfatal progression of heart 
failure in surviving patients.
Methods
The design and primary results of the PARADIGM-HF trial have 
been previously described.12 The institutional review board of each 
of the 1043 participating institutions (in 47 countries) approved the 
protocol, and all patients gave written, informed consent.
Study Patients
Patients had New York Heart Association (NYHA) class II to IV 
symptoms, an ejection fraction of ≤40% (changed to ≤35% by 
amendment), and a plasma B-type natriuretic peptide (BNP) ≥150 
pg/mL (or N-terminal pro-BNP [NTproBNP] ≥600 pg/mL). Patients 
with lower levels of natriuretic peptides were eligible if they had 
been hospitalized for heart failure within 12 months.12 Patients tak-
ing any dose of ACE inhibitors or angiotensin receptor blockers were 
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considered for enrollment, but were required to tolerate the equiva-
lent of enalapril 10 mg daily for at least 4 weeks before screening 
along with stable doses of a β-blocker (unless contraindicated or not 
tolerated) and a mineralocorticoid antagonist (if indicated). Among 
the exclusion criteria,12 patients were not eligible for the trial if they 
had a history of intolerance of ACE inhibitors or angiotensin receptor 
blockers.
Study Procedures
On trial entry, ongoing therapy with an ACE inhibitor or angiotensin 
receptor blocker was stopped, but other treatments for heart failure 
were continued. Patients first received enalapril 10 mg twice daily for 
2 weeks (single-blind) and then LCZ696 (single-blind) for an addi-
tional 4 to 6 weeks, initially at 100 mg twice daily and then 200 mg 
twice daily. To minimize the potential for angioedema, enalapril was 
withheld a day before starting LCZ696, and LCZ696 was withheld a 
day before starting randomized therapy. Patients tolerating both drugs 
at target doses were randomly assigned in a 1:1 ratio to double-blind 
treatment with either enalapril 10 mg twice daily or LCZ696 200 mg 
twice daily. The dose of enalapril was selected based on its effect to 
reduce the risk of death in the Studies of Left Ventricular Dysfunction 
(SOLVD) Treatment Trial19; higher doses have not been more effec-
tive or well tolerated during long-term treatment.20–22 Following ran-
domization, patients were maintained on the highest tolerated doses 
of the study medication. Surviving patients underwent periodic evalu-
ation of NYHA functional class, symptoms of heart failure (measured 
by using the Kansas City Cardiomyopathy Questionnaire [KCCQ]),23 
and, in approximately 27% of randomized patients, biomarkers of 
neprilysin inhibition and heart failure progression. Worsening heart 
failure was treated by adjusting the doses of any concomitant drug 
and using any interventions that were clinically indicated.
Statistical Analysis
The trial was designed to recruit ≈8000 patients and continue until the 
occurrence of 1229 cardiovascular deaths and 2410 cardiovascular 
deaths or first hospitalizations for heart failure. However, an inde-
pendent Data and Safety Monitoring Board recommended early ter-
mination of the study (approximately 50 months after the first patient 
was randomized) when the boundary for overwhelming benefit for 
cardiovascular mortality had been crossed.
The principal analyses for this article focused on (1) worsening 
NYHA functional class, as assessed by the physician; (2) worsening 
KCCQ total symptom score, as assessed by the patient; (3) worsen-
ing heart failure requiring an increase in the dose of diuretic for >1 
month, the addition of a new drug for heart failure, or the use of intra-
venous therapy (prospectively defined in the protocol as a treatment 
failure); (4) worsening heart failure leading to an emergency depart-
ment visit (without subsequent hospitalization); (5) worsening heart 
failure requiring hospitalization, with a prespecified analysis at 30 
days after randomization; (6) the use of interventions for advancing 
heart failure; and (7) changes in biomarkers reflecting cardiac injury, 
wall stress, and the effects of neprilysin inhibition. All deaths and 
all hospitalizations possibly related to heart failure were adjudicated 
blindly according to prespecified criteria by a clinical-events com-
mittee, which had no knowledge of the patient’s drug assignment. Of 
the 4 biomarkers of interest, plasma NTproBNP and troponin T were 
measured by using the Roche Elecsys proBNP and high-sensitivity 
Troponin T assays (Roche Diagnostics GmbH, Germany); plasma 
BNP was measured by using the Advia Centaur assay (Siemens, 
USA); and cGMP was measured in first-morning-void urine samples 
by using an enzyme-linked immunosorbent assay (R & D Systems, 
USA). Data on all outcome measures were collected prospectively, 
and their analyses were prespecified as end points of interest.
Cox proportional hazards regression models (with treatment and 
region as fixed-effect factors) were used to evaluate between-group 
differences in time-to-event end points and to estimate hazard ratios, 
95% confidence intervals, and P values. Negative binomial models 
(with treatment and region as fixed factors and logarithm of the dura-
tion of follow-up as the offset),24 Wilcoxon rank-sum test, and Fisher 
exact test were used to assess the significance of differences in the 
number, rate and duration of hospital admissions and emergency 
department visits; of the use of medical and device interventions for 
advancing heart failure; and of clinical worsening by ≥1 NYHA func-
tional class and ≥5 points in the KCCQ total symptom score (based 
on the magnitude of change considered to be clinically relevant).21
The rate of total hospitalizations for heart failure was calculated by 
the Nelson-Aalen estimate,25 ignoring death as a potential informative 
dropout. Ignoring death as a potential informative dropout may lead 
to underestimation of the magnitude of the treatment effects in our 
analysis, because heart failure morbidity and mortality are strongly 
associated, and thus, the censoring of patients at the time of death 
can be expected to minimize estimates of the rate of worsening heart 
failure events in the group with a poorer survival.26 Nevertheless, all 
analyses were performed on data available at each time point; no 
imputation was applied to patients who died or had missing data.
Results
Study Patients and Study Drug Administration
A total of 10 521 patients at 1043 centers in 47 countries 
entered the run-in period, of whom 8399 patients were ran-
domly assigned and prospectively included in the intention-
to-treat analysis (4187 to LCZ696 and 4212 or enalapril). 
As previously reported,12 the 2 groups comprised primarily 
patients with mild-to-moderate symptoms who were well 
treated with diuretics, β-blockers, and mineralocorticoid 
receptor antagonists and were balanced with respect to base-
line characteristics. Excluding patients who died, 87% of both 
the LCZ696 and enalapril groups were receiving the target 
dose of the study drug at 8 months; and 76% and 75%, respec-
tively, were maintained at the target dose at the end of the 
study.
Effect on Death or Hospitalization for Any Reason
There were 835 patients in the enalapril group and 711 in the 
LCZ696 group who died for any reason, corresponding to 
annualized rates of 7.5% and 6.0%, respectively. These dif-
ferences reflected a 16% incremental reduction in the risk of 
death (hazard ratio, 0.84; 95% confidence interval [CI], 0.76–
0.93, P=0.0009). There were 2093 patients who died or who 
were hospitalized for any reason in the enalapril group and 
1892 such patients in the LCZ696 group, corresponding to 
annualized rates of 30.3% and 26.3%, respectively. These dif-
ferences reflected a 12.6% lower risk as a result of treatment 
with LCZ696 instead of enalapril (hazard ratio, 0.87; 95% CI, 
0.82–0.93; P<0.0001).
Effect on Occurrence of Clinical Worsening
In comparison with enalapril-treated patients, there were 
fewer LCZ696-treated patients who had worsening heart fail-
ure requiring the addition of a new drug, intravenous therapy, 
or an increase in the daily dose of diuretic for >1 month (520 
versus 604; hazard ratio, 0.84; 95% CI, 0.74–0.94; P=0.003). 
Fewer patients in the LCZ696 group than in the enalapril 
group were evaluated and treated for worsening heart failure 
in the emergency department but discharged without hospital 
admission (102 versus 150; hazard ratio, 0.66; 95% CI, 0.52-
0.85; P=0.001; Table). When all (including repeat) emergency 
department evaluations for heart failure were considered, the 
LCZ696 group had 30% lower rate of such visits than the enala-
pril group (P=0.017).
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Table.  Measures of Nonfatal Worsening Heart Failure in the Enalapril and LCZ696 Groups
Enalapril
(n=4212)
LCZ696
(n=4187)
Hazard/Rate Ratio (95% CI)
P Value
Patients with worsening heart failure leading to intensification of outpatient 
therapy, n (%)
604 (14.3) 520 (12.4) 0.84 (0.74–0.94)
0.003
Patients with worsening NYHA functional class (≥1 class)
  In patients surviving at 4 mo, n (%) 218 (5.5) 186 (4.7) 0.113
  In patients surviving at 8 mo, n (%) 266 (7.0) 205 (5.4) 0.004
  In patients surviving at 12 mo, n (%) 271 (7.4) 225 (6.1) 0.023
Patients with worsening KCCQ total symptoms score (≥5 points)
  In patients surviving at 4 mo, n (%) 1012 (28.3) 899 (25.1) 0.002
  In patients surviving at 8 mo, n (%) 1087 (31.8) 974 (28.2) 0.001
  In patients surviving at 12 mo, n (%) 1029 (31.5) 964 (29.0) 0.03
Patients with ED visit for heart failure, n (%) 150 (3.6) 102 (2.4) 0.66 (0.52–0.85)  
0.001
  Patients with 1 ED visit for heart failure, n (%) 111 (2.6) 78 (1.9) 0.003
  Patients with 2 ED visits for heart failure, n (%) 27 (0.6) 15 (0.4)
  Patients with ≥3 ED visits for heart failure, n (%) 12 (0.3) 9 (0.2)
Total number of ED visits for heart failure 208 151 0.70 (0.52–0.94)*
0.017
Patients hospitalized for heart failure, n (%) 658 (15.6) 537 (12.8) 0.79 (0.71–0.89)
<0.001
  Patients with 1 admission for heart failure, n (%) 418 (9.9) 367 (8.8)
<0.001
  Patients with 2 admissions for heart failure, n (%) 143 (3.4) 110 (2.6)
  Patients with 3 admissions for heart failure, n (%) 53 (1.3) 33 (0.8)
  Patients with ≥ 4 admissions for heart failure, n (%) 44 (1.0) 27 (0.6)
Total number of hospitalizations for heart failure 1079 851 0.77 (0.67–0.89)*
<0.001
Number of days in the hospital per admission per patient 9.7±9.5 10.8±17.5 0.86
Number of patients requiring intensive care 623 549 0.87 (0.78–0.98)
0.019
Total number of stays in intensive care 879 768 0.82 (0.72–0.94)*
0.005
Patients receiving IV positive inotropic drugs, n (%) 229 (5.4) 161 (3.9) 0.69 (0.57–0.85)
<0.001
Patients requiring cardiac resynchronization, ventricular assist device 
implantation, or cardiac transplantation, n (%)
119 (2.8) 94 (2.3) 0.78 (0.60–1.02)
0.07
Patients hospitalized for cardiovascular reason, n (%) 1344 (31.9) 1210 (28.9) 0.88 (0.81–0.95)
<0.001
Total number of hospitalizations for cardiovascular reason 2537 2216 0.84 (0.76–0.92)*  
<0.001
Patients hospitalized for any reason, n (%) 1827 (43.4) 1660 (39.7) 0.88 (0.82–0.94)
<0.001
Total number of hospitalizations for any reason 4053 3564 0.84 (0.78–0.91)* 
<0.001
CI indicates confidence interval; ED, emergency department; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; and NYHA, New York Heart Association. 
*Asterisk denotes rate ratio estimated from a negative binomial model; ratios without an asterisk are hazard ratios derived by using the Cox proportional hazards 
model. 
Fewer patients in the LCZ696 group than in the enalapril 
group were hospitalized for heart failure (hazard ratio, 0.79; 
95% CI, 0.71–0.89; P<0.001), for a cardiovascular reason 
(hazard ratio, 0.88; 95% CI, 0.81–0.95; P<0.001) or for any 
reason (hazard ratio, 0.88; 95% CI, 0.82–0.94; P<0.001; 
Table). The between-group difference in the risk of hospital-
ization for heart failure was statistically significant as early 
as 30 days following randomization (hazard ratio at 30 days, 
0.60; 95% CI, 0.38–0.94; P=0.027; Figure 1).
In comparison with enalapril, patients treated with 
LCZ696 were not only less likely to be hospitalized for heart 
failure at least once, but were also less likely to be hospital-
ized multiple times; 240 patients in the enalapril group but 
only 170 patients in the LCZ696 group were hospitalized 
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for heart failure more than once (a 29% reduction in the 
LCZ696 group, P=0.001). When all (including repeat) hos-
pitalizations were considered, the LCZ696 group had 15.6% 
fewer hospitalizations than the enalapril group for any reason 
(P<0.001), 16.0% fewer hospitalizations for a cardiovascu-
lar reason (P<0.001), and 23.0% fewer admissions for heart 
failure (P<0.001) than patients in the enalapril group (Table). 
The cumulative number of hospitalizations for heart failure 
per 100 patients is shown in Figure 2. The 2 groups were 
similar with respect to the average duration of each admission 
for heart failure, but, in comparison with the enalapril group, 
the patients in the LCZ696 group had 18% fewer stays in 
intensive care (P=0.005) and were 31% less likely to receive 
intravenous positive inotropic agents (P<0.001) and 22% less 
likely to have cardiac transplantation or implantation of a car-
diac device for heart failure (P=0.07). The number of patients 
who received a left ventricular assist device or underwent car-
diac transplantation was 23 in the enalapril group and 13 in 
the LCZ696 group.
Despite greater intensification of treatment and greater loss 
of more severely ill patients because of death in the enala-
pril group, a larger proportion of surviving patients in that 
group were considered by their physicians to be worse (by 
at least 1 NYHA class) than in the LCZ696 group; the dif-
ference between the 2 groups was significant at both 8 and 
12 months of follow-up (P=0.004 and P=0.023, respectively; 
Table). Moreover, fewer surviving patients considered them-
selves worse (by at least 5 points in the KCCQ total symptom 
score) in the LCZ696 group than in the enalapril group; the 
difference between the groups was significant at 4, 8, and 12 
months (P=0.002, P=0.001, and P=0.03, respectively; Table).
Effect on Biomarkers of Heart Failure Progression
Levels of urinary cyclic GMP and plasma BNP were 
higher during treatment with LCZ696 than with enalapril 
(Figure 3A), but circulating levels of NTproBNP and troponin 
were lower during treatment with LCZ696 than with enalapril 
(Figure 3B). The differences between groups were apparent 
within 4 weeks and were sustained at 8 months, P<0.0001 for 
the difference between groups at both time points.
Discussion
In patients with a reduced ejection fraction and mild-to-
moderate symptoms, combined inhibition of the angioten-
sin receptor and neprilysin with LCZ696 reduced the risk of 
developing worsening heart failure more than ACE inhibition 
with enalapril. Fewer patients in the LCZ696 group were con-
sidered to be worse by themselves or by their physicians, and 
fewer patients in the LCZ696 group had worsening symptoms 
requiring intensification of outpatient therapy or the use of 
medical or device treatments for advancing heart failure.
Not only was LCZ696 superior to enalapril in reducing the 
risk of a first emergency department visit or hospitalization 
for heart failure, but the drug was also more effective than 
ACE inhibition alone in decreasing the need for repeated 
emergency visits and hospitalizations for heart failure. These 
advantages were apparent even though (1) the enalapril group 
had a meaningfully higher mortality rate throughout the trial, 
leading to the preferential exclusion of high-risk enalapril-
treated patients with progressing symptoms from our analy-
ses; and (2) the enalapril group had greater intensification of 
background therapy, which would have been expected to ame-
liorate deleterious changes in clinical status. Therefore, the 
observed effect sizes reported in our analyses may underesti-
mate the true magnitude of the treatment difference. Despite 
the biases against the drug, LCZ696 was superior to enalapril 
in reducing the risk of symptom progression and exerting a 
favorable effect on the clinical course of surviving patients 
with mild-to-moderate heart failure.
Few trials have focused on the ability of new drugs to 
prevent worsening of clinical status in patients with mild-
to-moderate heart failure.27 Previous studies in such patients 
0 10 20 30
0.5
1.0
1.5
0.0K
-M
 E
st
im
at
e 
of
 C
um
ul
at
iv
e 
R
at
e
Days After Randomization
4187
4212
4174
4192
4153
4166
4140
4143
LCZ696
Enalapril
Patients at Risk
Enalapril
(n=4212)
LCZ696
(n=4187)
Hazard ratio 0.60 (0.38-0.94)
P = 0.027
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the cumulative probability of a first hospitalization for heart failure 
during the first 30 days after randomization. The analysis at  
30 days was prespecified and also represented the earliest time 
point, at which the difference between the LCZ696 and enalapril 
groups was statistically significant. K-M indicates Kaplan–Meier.
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Figure 2. Cumulative number of hospitalizations for heart failure 
in the enalapril and LCZ696 groups per 100 patients. Shown is 
the cumulative number of hospitalizations for heart failure in the 
2 study groups per 100 patients, ignoring death as an informative 
dropout, with the rate ratio calculated by using the negative 
binomial regression model. 
Packer et al  Angiotensin Neprilysin Inhibition in Heart Failure  59
have primarily reported improvements in exercise tolerance 
or functional class or decreases in the risk of hospitaliza-
tion for heart failure.28–30 In the few trials that have reported 
worsening of symptoms, quality of life, or functional class, 
active treatments produced a meaningful reduction in the risk 
of clinical worsening only when missing data were imputed 
or when patients who died were included in the analysis 
and assigned the worst possible score.29,31–33 In contrast, the 
PARADIGM-HF study is among the first trials to demon-
strate a reduction of clinical worsening of surviving patients, 
which is not only of paramount importance to those afflicted 
with the disease and their families, but also to the physicians 
who care for them and the insurers who pay for the intensifi-
cation of treatments. The advantage of LCZ696 over enalapril 
in preventing clinical deterioration was apparent early in the 
trial and persisted for the duration of double-blind therapy.
Our clinical findings are supported by the effects on 
biomarkers measured in surviving patients in the trial. As 
expected from neprilysin inhibition,34 levels of both urinary 
cyclic GMP and plasma BNP were higher during treatment 
with LCZ696 than with enalapril; the increases in cyclic 
GMP reflect the fact that the peptides whose levels are 
enhanced by neprilysin inhibition act through enhancement 
of cyclic GMP.35–37 In contrast, in comparison with enalapril, 
patients receiving LCZ696 had consistently lower levels of 
NTproBNP (reflecting reduced cardiac wall stress) and tro-
ponin (reflecting reduced cardiac injury) throughout the trial. 
The contrasting effects of LCZ696 on the 2 types of natri-
uretic peptides represents an important finding, because the 
levels of the 2 peptides characteristically parallel each other 
during the course of heart failure.38 However, because BNP 
(but not NTproBNP) is a substrate for neprilysin,39 levels 
of BNP will reflect the action of the drug, whereas levels of 
NTproBNP will reflect the effects of the drug on the heart. 
Furthermore, although differences in the levels of troponin 
between the 2 treatment groups were small, even very low 
levels of troponin release are believed to reflect ongoing myo-
cardial injury (possibly related to increased wall stress),40 and 
even small increases in the levels of troponin reflect a higher 
risk of disease progression in heart failure.41,42
In conclusion, in comparison with guideline-recommended 
doses of an ACE inhibitor, combined inhibition of both the 
angiotensin receptor and neprilysin was more effective not 
only in reducing all-cause and cardiovascular mortality,12 but 
also in reducing the risks and rates of multiple manifestations 
of clinical deterioration of surviving patients with heart fail-
ure. The effect of LCZ696 to stabilize the course of heart fail-
ure is likely to have important ramifications for both quality of 
life and resource utilization in this disorder.
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Figure 3. A, Median values for N-terminal pro-BNP and 
troponin T at entry and during single-blind run-in and double-
blind periods. Medians are shown in circles, and 25%/75% 
interquartile ranges are shown in bars, where patients in the 
LCZ696 group are shown in white circles and white bars and 
patients in the enalapril group are shown in black circles and gray 
bars. P values designate the significance of difference between 
the 2 treatment groups. Troponin T was not measured at the end 
of the enalapril phase of the run-in period. B, Median values for 
B-type natriuretic peptide and urinary cyclic GMP at entry and 
during single-blind run-in and double-blind periods. Medians are 
shown in circles, and 25%/75% interquartile ranges are shown 
in bars, where patients in the LCZ696 group are shown in white 
circles and white bars and patients in the enalapril group are 
shown in black circles and gray bars. P values designate the 
significance of the difference between the 2 treatment groups. 
Urinary cyclic GMP was not measured at the end of the enalapril 
phase of the run-in period. BNP indicates B-type natriuretic 
peptide; ENL, end of the enalapril phase of the run-in period; and 
LCZ, end of the LCZ696 phase of the run-in period.
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CLINICAL PERSPECTIvE
The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity 
in Heart Failure) trial compared the angiotensin receptor-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-
converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a dou-
ble-blind trial. In a previous report, patients in the LCZ696 group had a 20% lower risk of cardiovascular death and a 16% 
lower risk of death for any reason (both P<0.0001). This article reports on the effect of treatment on the clinical progression 
of heart failure in surviving patients. When compared with enalapril, fewer LCZ696-treated patients required intensification 
of medical treatment for heart failure (P=0.003) or an emergency department visit for worsening heart failure (P=0.001). 
The patients in the LCZ696 group also had 23% fewer hospitalizations for worsening heart failure (P<0.001) and were 18% 
less likely to require intensive care (P=0.005), 31% less likely to receive intravenous positive inotropic agents (P<0.001), 
and 22% less likely to have implantation of a heart failure device or cardiac transplantation (P=0.07). The reduction in heart 
failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening symptoms of heart 
failure were consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomark-
ers of myocardial wall stress and injury (N-terminal pro–B-type natriuretic peptide and troponin) versus enalapril. These 
findings demonstrate that LCZ696 prevents the clinical progression of surviving patients more effectively than enalapril and 
provides further support for the use of this new approach to replace the current use of inhibitors of the renin-angiotensin 
system in chronic heart failure.
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